The results of treatment for resectable gastric cancer with microsatellite instability
Authors:
- H. SunHSH. Sun
- S. N. NeredSNS. N. Nered
- A. A. TryakinATA. A. Tryakin
- E. V. ArtamonovaEAE. V. Artamonova
- A. E. KalininAKA. E. Kalinin
- V. E. BugaevVBV. E. Bugaev
- N. S. BesovaNBN. S. Besova
- P. P. ArkhiriPAP. P. Arkhiri
- V. I. MarshallVMV. I. Marshall
- R. Sh. AbdulaevaRAR. Sh. Abdulaeva
- I. S. StilidiISI. S. Stilidi
Open Access
- 23 June 2023
- journal article
- research article
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 13 (2) , 17-26
Abstract
Background. microsatellite instability (MSI) is a prognostic marker of survival in many malignant diseases and show resistance to chemotherapy at early stages of colorectal cancer and show no benefits from chemotherapy at early stages of colorectal cancer. However, the role of MSI in resectable gastric cancer (GC) remains unknown.Aim. To study the results of treatment of resectable gastric cancer with microsatellite instability.Materials and methods. The study included 286 patients with resectable gC who received treatment at the N. N. Blokhin national medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the mandard tumour regression score, including disease-free survival and overall survival.Results. MSI indicated in 27 cases (9.44 %) out of 286 resectable gastric cancer. In group patients who received only surgical treatment, 2-year disease-free survival in patients with MSI-H was 77.80 % versus 88.29 % in MSS patients (hazard ratio (HR) 1.82, 95 % confidence interval (CI) 0.37–8.82, p = 0.45), 2-year overall survival in patients with MSI-H was 88.90 % versus 95.36 % in MSS patients (HR 2.03, 95 % CI 0.20–19.8, p = 0.54). In patients who received perioperative chemotherapy, 28.57 % (4 / 14) had progression in MSI-H tumor versus 3.61 % (6 / 166) in MSS tumor (p 0.001). In group patients who received treatment combined with chemotherapy, 2-year disease-free survival in patients with MSI-H was 59.60 % versus 67.36 % (HR 1.96, CI 95 % 0.88–4.35, p = 0.09), 2-year overall survival in patients with MSI-H was 67.30 % versus 85.86 % in MSS patients (HR 1.86, 95 % CI 0.64–5.41, p = 0.25)Conclusion. MSI-H is not a favorable prognosis factor in patients with resectable GC who are treated surgically combined with chemotherapy. The prevalence of progression in patients with MSI-H-status is higher than MSS-status with perioperative chemotherapy (FLOT / FOLFIRINOX).Keywords
This publication has 37 references indexed in Scilit:
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJournal of Clinical Oncology, 2011
- Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5‐FU based chemotherapy after R0 resectionInternational Journal of Cancer, 2011
- Chemosensitivity and Survival in Gastric Cancer Patients with Microsatellite InstabilityAnnals of Surgical Oncology, 2009
- Clinicopathologic characteristics and outcomes of gastric cancers with the MSI‐H phenotypeJournal of Surgical Oncology, 2008
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Patterns of genomic instability in gastric cancer: clinical implications and perspectivesAnnals of Oncology, 2006
- Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancersSurgery, 2006
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Distinct Clinical Features and Outcomes of Gastric Cancers with Microsatellite InstabilityLaboratory Investigation, 2002
- Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stagesEuropean Journal of Cancer, 1995